España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Cytokinetics
CYTK
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$48.87
2.13
4.56%
At close: -
$48.87
-0.00050
0.00%
After Hours: Dec 20, 4:00 PM EDT
Get Report
Comment
Cytokinetics (CYTK) sold assets to Sanofi (SNY) on Friday, December 20, 2024
Cytokinetics (CYTK) Forecast
News
Earnings
Cytokinetics (CYTK) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Cytokinetics (NASDAQ:CYTK) Stock
Cytokinetics Stock (NASDAQ: CYTK)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, December 20, 2024
Cytokinetics shares are trading higher after ...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Cytokinetics Announces Sanofi's Acquisition O...
Benzinga Newsdesk
Wednesday, December 18, 2024
RBC Capital Maintains Outperform on Cytokinet...
Benzinga Newsdesk
Tuesday, December 03, 2024
Cytokinetics Launches Phase 3 COMET-HF Trial ...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Monday, December 02, 2024
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Needham Reiterates Buy on Cytokinetics, Maint...
Benzinga Newsdesk
The FDA Has Accepted Cytokinetics' New Drug A...
Benzinga Newsdesk
Thursday, November 21, 2024
Mizuho Maintains Outperform on Cytokinetics, ...
Benzinga Newsdesk
Wednesday, November 20, 2024
Needham Reiterates Buy on Cytokinetics, Maint...
Benzinga Newsdesk
Tuesday, November 19, 2024
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Cytokinetics And Bayer Partner For Exclusive ...
Benzinga Newsdesk
Monday, November 18, 2024
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Reported Saturday, Cytokinetics Unveils New D...
Benzinga Newsdesk
Reported Saturday, Cytokinetics Shares Additi...
Benzinga Newsdesk
Monday, November 11, 2024
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Cytokinetics Initiates Phase 1 Clinical Study...
Benzinga Newsdesk
Friday, November 08, 2024
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Avi Kapoor
RBC Capital Initiates Coverage On Cytokinetic...
Benzinga Newsdesk
Thursday, November 07, 2024
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Wednesday, November 06, 2024
Cytokinetics Q3 EPS $(1.36) Misses $(1.26) Es...
Benzinga Newsdesk
Tuesday, November 05, 2024
Cytek Biosciences shares are trading higher f...
Benzinga Newsdesk
Friday, October 18, 2024
Cantor Fitzgerald Reiterates Overweight on Cy...
Benzinga Newsdesk
Thursday, October 17, 2024
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Needham Reiterates Buy on Cytokinetics, Maint...
Benzinga Newsdesk
Wednesday, October 16, 2024
Cytokinetics Will Provide An Update On Cardia...
Benzinga Newsdesk
Wednesday, October 09, 2024
Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor
HC Wainwright & Co. Maintains Buy on Cytokine...
Benzinga Newsdesk
Monday, September 30, 2024
Analysts Think There's Still Time To Get In On Edgewise
MarketBeat
Cytokinetics Presents Additional SEQUOIA-HCM ...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Friday, September 27, 2024
Cytokinetics Presents Additional Data From SE...
Benzinga Newsdesk
Friday, September 20, 2024
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Thursday, September 19, 2024
Cytokinetics Announces Upcoming Presentations...
Benzinga Newsdesk
Friday, September 13, 2024
Cytokinetics's Options Frenzy: What You Need to Know
Benzinga Insights
Monday, September 09, 2024
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study
Vandana Singh
Cantor Fitzgerald Reiterates Overweight on Cy...
Benzinga Newsdesk
Cytokinetics' CK-586 Advances After Phase 1 R...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Thursday, September 05, 2024
Cytokinetics Announces Two Presentations At T...
Benzinga Newsdesk
JP Morgan Maintains Overweight on Cytokinetic...
Benzinga Newsdesk
Wednesday, September 04, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Tuesday, September 03, 2024
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Needham Reiterates Buy on Cytokinetics, Maint...
Benzinga Newsdesk
Reported Earlier, Cytokinetics Presents New S...
Benzinga Newsdesk
Thursday, August 22, 2024
Cytokinetics Unusual Options Activity For August 22
Benzinga Insights
Tuesday, August 13, 2024
Goldman Sachs Downgrades Cytokinetics to Neut...
Benzinga Newsdesk
Monday, August 12, 2024
HC Wainwright & Co. Reiterates Buy on Cytokin...
Benzinga Newsdesk
Friday, August 09, 2024
Needham Reiterates Buy on Cytokinetics, Maint...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
